RSAR: Post-marketing RX Drug Abuse Surveillance Data - IBH (Data Source)

The Food and Drug Administration is forecasting a recompete for the Post-marketing RX Drug Abuse Surveillance Data contract under the IBH data source for fiscal year 2026. This initiative falls under NAICS code 541990 and is managed by the agency's Center for Drug Evaluation and Research. The primary objective of this effort is to maintain surveillance data regarding the abuse of prescription drugs following their market release. Interested parties can coordinate with the Cder Acquisition Liaison for further program details as the agency prepares for the formal solicitation process.